Most published case reports claiming cannabis fights cancer provide insufficient evidence

Of 207 pre-clinical articles, 107 contained original data showing anticancer activity. Of 77 published case reports, only 14% met strong criteria (active cancer, validated response, no concurrent treatment), 5% were moderate, and 81% were weak. CBD was the most reported anticancer cannabinoid (10-800 mg/day). Two small trials reported survival data for glioblastoma. Nearly 40% of cancer patients using cannabis believe it will treat their cancer.

Literature review of PubMed, EBSCO, ClinicalTrials.gov, online sources, and books. All case reports appraised as weak, moderate, or strong based on three criteria: active cancer at cannabis administration, validated lab/radiographic responses, and cannabis use without concurrent anticancer treatments.

Numerous anecdotal reports shared on social media create unrealistic expectations. This systematic appraisal shows that most published case reports do not meet basic evidence standards.

The disconnect between over 100 positive preclinical studies and the lack of strong clinical evidence highlights the difficulty of translating lab findings to human cancer treatment.

Case reports inherently cannot prove causation. Strong criteria were defined by the authors. Publication bias favors positive case reports. Online anecdotal claims were not systematically assessed.